UA79952C2 - MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT - Google Patents
MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT Download PDFInfo
- Publication number
- UA79952C2 UA79952C2 UA20040705575A UA20040705575A UA79952C2 UA 79952 C2 UA79952 C2 UA 79952C2 UA 20040705575 A UA20040705575 A UA 20040705575A UA 20040705575 A UA20040705575 A UA 20040705575A UA 79952 C2 UA79952 C2 UA 79952C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cancer
- administered
- differs
- fact
- drug
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 52
- 201000011510 cancer Diseases 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 241001494992 Mycobacterium indicus pranii Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 48
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 238000002512 chemotherapy Methods 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 14
- 239000003755 preservative agent Substances 0.000 claims description 14
- 230000002335 preservative effect Effects 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 230000003902 lesion Effects 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 4
- 239000002480 mineral oil Substances 0.000 claims 4
- 235000010446 mineral oil Nutrition 0.000 claims 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 4
- 238000000855 fermentation Methods 0.000 claims 3
- 230000004151 fermentation Effects 0.000 claims 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 2
- 229920003345 Elvax® Polymers 0.000 claims 2
- 239000000020 Nitrocellulose Substances 0.000 claims 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- 239000013043 chemical agent Substances 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 229920001220 nitrocellulos Polymers 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 229940031439 squalene Drugs 0.000 claims 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 abstract description 8
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 229910002651 NO3 Inorganic materials 0.000 abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract description 3
- 108010046334 Urease Proteins 0.000 abstract description 3
- 241001506930 atypical mycobacterium Species 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000000825 pharmaceutical preparation Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229940126585 therapeutic drug Drugs 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000852 deltoid muscle Anatomy 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 239000000147 enterotoxin Substances 0.000 description 6
- 231100000655 enterotoxin Toxicity 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
- 206010024229 Leprosy Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000011443 conventional therapy Methods 0.000 description 3
- 238000002574 cystoscopy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000002476 tumorcidal effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000005242 bronchial neoplasm Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000006997 middlebrook medium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000009268 pathologic speech processing Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000009801 radical cystectomy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1167MU2001 | 2001-12-10 | ||
| PCT/IB2002/005516 WO2003049667A2 (en) | 2001-12-10 | 2002-12-10 | The method of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79952C2 true UA79952C2 (en) | 2007-08-10 |
Family
ID=11097334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705575A UA79952C2 (en) | 2001-12-10 | 2002-10-12 | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7972609B2 (enExample) |
| JP (1) | JP4527979B2 (enExample) |
| AP (1) | AP1896A (enExample) |
| AU (1) | AU2002348738B2 (enExample) |
| CA (1) | CA2469266C (enExample) |
| GB (1) | GB2389532C (enExample) |
| NZ (1) | NZ533417A (enExample) |
| UA (1) | UA79952C2 (enExample) |
| WO (1) | WO2003049667A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2632353C (en) | 2005-04-25 | 2018-02-20 | Bakulesh Mafatlal Khamar | Vaccine adjuvants comprising mycobaterium |
| AU2007323134B2 (en) * | 2006-11-23 | 2013-05-02 | Cadila Pharmaceuticals Limited | Poly-TLR antagonist |
| CA2681420A1 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
| AU2008269427A1 (en) * | 2007-06-28 | 2008-12-31 | Cadila Pharmaceuticals Ltd. | Mitogen activated protein kinase modulator |
| WO2011083493A1 (en) * | 2010-01-08 | 2011-07-14 | National Institute Of Immunology | Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer |
| CN102753975B (zh) * | 2010-02-19 | 2015-05-20 | 卡帝拉药物有限公司 | 基本上保留免疫原性的被杀死细胞的药物组合物 |
| WO2012049654A1 (en) * | 2010-10-13 | 2012-04-19 | Bioniche Life Sciences, Inc. | Bacterial ribonucleic acid cell wall compositions and methods of making and using them |
| PL2663318T3 (pl) * | 2011-01-11 | 2015-08-31 | Cadila Pharmaceuticals Ltd | Kompozycja farmaceutyczna do leczenia raka |
| TR201101874A2 (tr) * | 2011-02-25 | 2011-08-22 | Leyla A�An Nac�Ye | Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri. |
| CA2828401C (en) * | 2011-02-28 | 2023-01-10 | Cadila Pharmaceuticals Limited | Therapeutic cancer vaccine |
| ES2647768T3 (es) * | 2011-07-05 | 2017-12-26 | Cadila Pharmaceuticals Limited | Antígeno de cáncer |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US6126945A (en) | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| IL105503A (en) | 1992-04-28 | 1999-05-09 | Astra Ab | Carbon peptide couplets capable of eliciting an immune response of T cells |
| GB9223816D0 (en) * | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
| US5767156A (en) | 1993-10-06 | 1998-06-16 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| US6090385A (en) | 1993-12-10 | 2000-07-18 | Maes; Hubert | Method of treating cancer |
| GB9406301D0 (en) * | 1994-03-30 | 1994-05-25 | Univ London | Immunotherapeutic agent and its use |
| US6056964A (en) | 1995-03-29 | 2000-05-02 | Stanford Rook Limited | Immunotherapeutic agent and its use |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US5869645A (en) | 1997-10-15 | 1999-02-09 | Board Of Trustees Of The University Of Illinois | Method for isolating high molecular weight antineoplastic glycans using urea |
| AUPP437698A0 (en) * | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| BR0303367A (pt) * | 2002-03-08 | 2004-07-20 | Bakulesh Mafatlal Khamar | Células de mycobacterium w, veìculo farmaceuticamente aceitável, preservativo, ruptura de mycobacterium w, extração de solvente, enzimas usadas para a extração enzimática de células de mycobacterium w, adjuvante, composição farmacêutica, tensoativo, e, concentração de tensoativo do processo de fabricar uma composição farmacêutica para a administração de tuberculose |
-
2002
- 2002-10-12 UA UA20040705575A patent/UA79952C2/uk unknown
- 2002-12-10 JP JP2003550718A patent/JP4527979B2/ja not_active Expired - Fee Related
- 2002-12-10 AU AU2002348738A patent/AU2002348738B2/en not_active Ceased
- 2002-12-10 WO PCT/IB2002/005516 patent/WO2003049667A2/en not_active Ceased
- 2002-12-10 NZ NZ533417A patent/NZ533417A/en not_active IP Right Cessation
- 2002-12-10 AP APAP/P/2004/003070A patent/AP1896A/en active
- 2002-12-10 US US10/502,417 patent/US7972609B2/en not_active Expired - Fee Related
- 2002-12-10 GB GB0322773A patent/GB2389532C/en not_active Expired - Fee Related
- 2002-12-10 CA CA2469266A patent/CA2469266C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002348738A1 (en) | 2003-06-23 |
| CA2469266C (en) | 2014-02-11 |
| JP4527979B2 (ja) | 2010-08-18 |
| CA2469266A1 (en) | 2003-06-19 |
| AP1896A (en) | 2008-10-08 |
| WO2003049667A2 (en) | 2003-06-19 |
| GB2389532A (en) | 2003-12-17 |
| US20070259005A1 (en) | 2007-11-08 |
| US7972609B2 (en) | 2011-07-05 |
| GB0322773D0 (en) | 2003-10-29 |
| NZ533417A (en) | 2008-04-30 |
| AP2004003070A0 (en) | 2004-06-30 |
| GB2389532B (en) | 2004-10-27 |
| JP2005528332A (ja) | 2005-09-22 |
| AU2002348738B2 (en) | 2007-11-08 |
| WO2003049667A3 (en) | 2003-10-09 |
| GB2389532C (en) | 2005-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1765391B1 (en) | Bacterial compositions for the treatment of cancer | |
| US4877611A (en) | Vaccine containing tumor antigens and adjuvants | |
| KR102008535B1 (ko) | 면역계를 조절하기 위한 면역학적 조성물 및 이의 용도, 질환의 치료와 예방을 위한 방법, 세포 재생을 유도하는 방법, 그리고 면역 반응의 소생을 위한 방법 | |
| JPS60155123A (ja) | 癌の診断・治療剤と製品、ならびに細胞及び体液性免疫防御の低能の治療剤と製品 | |
| JP4135190B2 (ja) | 免疫治療剤とその使用 | |
| JPH08508976A (ja) | 改善化免疫療法用組成物 | |
| WO2003049751A1 (en) | The process of manufacturing a pharmaceutical composition useful for management of cancer | |
| JP4527979B2 (ja) | 癌を治療する方法 | |
| US6726913B1 (en) | Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes | |
| WO2010031883A1 (es) | Agente inmunoterapéutico apropiado para la profilaxis primaria de la tuberculosis | |
| CA2383626A1 (en) | Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes | |
| CA2136870C (fr) | Complexe immunomodulateur anti-sida | |
| CN101816631A (zh) | 用于肿瘤治疗性疫苗的脂质体制剂及其制备方法 | |
| EP0969851B1 (fr) | Complexe immunomodulateur et son utilisation dans les affections par helicobacter | |
| AU2021399800A1 (en) | Compositions comprising bacteria for cancer immunotherapy |